Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ).
Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced the commencement of commercial sales of its core product, Efsubaglutide Alfa, for the treatment of type 2 diabetes in Macau. This milestone follows the recent approval of its biologics license application in the region, marking a significant step in the company’s global expansion efforts. While this development is promising, the company advises caution as it cannot guarantee the successful marketing of the product in Macau.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, focused on the development and commercialization of medical products, particularly in the treatment of type 2 diabetes. The company is actively pursuing global expansion of its core product, Efsubaglutide Alfa.
Average Trading Volume: 1,593,493
Find detailed analytics on 2591 stock on TipRanks’ Stock Analysis page.